Qichen Long
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Qichen Long has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Min Hu
Department of Laboratory Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; Center for Clinical Molecular Diagnostics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
7 shared publications Nijiao Qin
Department of Laboratory Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; Center for Clinical Molecular Diagnostics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
4 shared publicationsZiyang Li
Department of Laboratory Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; Center for Clinical Molecular Diagnostics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
4 shared publicationsBingchu Li
Department of Laboratory Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; Center for Clinical Molecular Diagnostics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
3 shared publications- Binghui Li
Department of Laboratory Medicine, The Second Xiangya Hospital, Central South University, Changsha, China
3 shared publications - Weimin Wu
Department of Laboratory Medicine, The Second Xiangya Hospital, Central South University, Changsha, China
3 shared publications
Latest Publications
- 1 October 2026
- Published by Elsevier in Clinica Chimica Acta
- Vol. 594, 122869
A rapid sequential salting-out/isoelectric precipitation LC-MS/MS method for quantifying cytokeratin 18 in human ascitic fluid
- 1 October 2026
- Published by Elsevier in Clinica Chimica Acta
- Vol. 594, 122869
A rapid sequential salting-out/isoelectric precipitation LC-MS/MS method for quantifying cytokeratin 18 in human ascitic fluid
- Open Access
- 29 April 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
A novel serum metabolite classifier for identifying Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) integrating metabolomics and machine learning
Metabolic dysfunction-associated steatotic liver disease (MASLD) presents a growing global health burden, while reliable non-invasive biomarkers for identi
- 29 April 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Open AccessA novel serum metabolite classifier for identifying Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) integrating metabolomics and machine learning
Metabolic dysfunction-associated steatotic liver disease (MASLD) presents a growing global health burden, while reliable non-invasive biomarkers for identi
- Open Access
- 1 March 2026
- Vol. 44 (3) , 267-275
3种液相色谱-串联质谱法检测脂溶性维生素的性能确认和一致性评价
精准测定脂溶性维生素A、D、E、K(VA、25(OH)D、VE、VK)水平对健康评估与疾病诊断具有重要价值,液相色谱-串联质谱法(LC-MS/MS)因其高特异性与灵敏度成为其主要检测手段,但方法间结果的可比性与一致性仍待提升。本研究依据CLSI C62及《液相色谱-质谱临床应用建议》,对3种LC-MS/MS方法检测脂溶性维生素的线性范围、检出限、定量限、精密度和准确度等进行系统评估。研究选取中南大学湘雅二医院于2022年8月至10月期间留存的40例剩余血清样本,采用3种LC-MS/MS方法进行脂溶性维生素检测。通过Passing-Bablok回归分析评估3种方法之间的相关性,绘制Bland-Altman图分析其相对偏差,并以一致性相关系数(CCC)评价3种方法检测结果的一致性。同时,比较不同方法在重新校准前后的检测一致性。研究结果显示,3种LC-MS/MS方法的总变异系数(CV)为2.7%~10.1%,加标回收率为88.8%~109.2%,表明其检测性能符合临床应用要求。一致性分析结果显示,其中两种方法在25(OH)D检测中表现出中等一致性(CCC=0.938),其余LC-MS/MS方法的一致性相关系数范围为0.322~0.853,存在一定差异。经统一校准品重新校准后,除VK外,其余脂溶性维生素的检测一致性明显改善,CCC提高至0.918~0.983。综上所述,3种LC-MS/MS方法在检测脂溶性维生素方面具备良好的性能,但方法间一致性尚存不足。通过使用统一校准品进行重新校准,可显著提升检测结果的一致性。本研究为分析脂溶性维生素临床质谱检测方法的一致化现状及其优化路径提供了数据支持,有助于提高检测结果的准确性与可靠性,从而为临床诊断与治疗提供更坚实的依据。
- 1 March 2026
- Vol. 44 (3) , 267-275
Open Access3种液相色谱-串联质谱法检测脂溶性维生素的性能确认和一致性评价
精准测定脂溶性维生素A、D、E、K(VA、25(OH)D、VE、VK)水平对健康评估与疾病诊断具有重要价值,液相色谱-串联质谱法(LC-MS/MS)因其高特异性与灵敏度成为其主要检测手段,但方法间结果的可比性与一致性仍待提升。本研究依据CLSI C62及《液相色谱-质谱临床应用建议》,对3种LC-MS/MS方法检测脂溶性维生素的线性范围、检出限、定量限、精密度和准确度等进行系统评估。研究选取中南大学湘雅二医院于2022年8月至10月期间留存的40例剩余血清样本,采用3种LC-MS/MS方法进行脂溶性维生素检测。通过Passing-Bablok回归分析评估3种方法之间的相关性,绘制Bland-Altman图分析其相对偏差,并以一致性相关系数(CCC)评价3种方法检测结果的一致性。同时,比较不同方法在重新校准前后的检测一致性。研究结果显示,3种LC-MS/MS方法的总变异系数(CV)为2.7%~10.1%,加标回收率为88.8%~109.2%,表明其检测性能符合临床应用要求。一致性分析结果显示,其中两种方法在25(OH)D检测中表现出中等一致性(CCC=0.938),其余LC-MS/MS方法的一致性相关系数范围为0.322~0.853,存在一定差异。经统一校准品重新校准后,除VK外,其余脂溶性维生素的检测一致性明显改善,CCC提高至0.918~0.983。综上所述,3种LC-MS/MS方法在检测脂溶性维生素方面具备良好的性能,但方法间一致性尚存不足。通过使用统一校准品进行重新校准,可显著提升检测结果的一致性。本研究为分析脂溶性维生素临床质谱检测方法的一致化现状及其优化路径提供了数据支持,有助于提高检测结果的准确性与可靠性,从而为临床诊断与治疗提供更坚实的依据。
- Open Access
- 1 January 2026
- Published by Aging and Disease in Aging and disease
Lipid Networks in Osteoarthritis: Context-Dependent Drivers, Hallmarks of Aging, and Clinical Translation
Osteoarthritis (OA) is an age-related condition affecting the entire joint. Abnormal lipid regulation may act as a trigger for disease onset, or result from inflammation or mechanical injury; alternatively, it may merely manifest as a detectable signal without any direct mechanistic significance. Given that causality cannot be determined based on abundance alone, we propose a compartment-cell temporal framework: pathogenic effects may arise when lipid composition, flux or localisation exceed the tissue’s adaptive capacity. Experimental evidence plays a causal role for certain cholesterol and fatty acid pathways, whilst human lipid research remains at the stage of exploring associations. Lipid stress, through dysregulation of organelles such as the endoplasmic reticulum and mitochondria, converges with common features of joint ageing—including cellular senescence, mitochondrial dysfunction, imbalances in autophagy and proteostasis, inflammation, and alterations in signalling—and may reconcile previous conflicting findings in areas such as apolipoprotein E and fatty acid oxidation. At the translational level, weight loss and metabolic management are feasible short-term strategies, and the prospects for lipid stratification are promising; however, testing has not yet met clinical diagnostic standards, and lipid nanoparticles have not yet been established as a therapeutic method. At present, they should be regarded as delivery vehicles; challenges such as joint preservation, deep tissue delivery, and safety still need to be overcome, and validation in human tissue is required. In summary, lipid research contributes to the classification and treatment of OA, but a strict distinction must be made between the maturity of causal evidence and mere correlation.
- 1 January 2026
- Published by Aging and Disease in Aging and disease
Open AccessLipid Networks in Osteoarthritis: Context-Dependent Drivers, Hallmarks of Aging, and Clinical Translation
Osteoarthritis (OA) is an age-related condition affecting the entire joint. Abnormal lipid regulation may act as a trigger for disease onset, or result from inflammation or mechanical injury; alternatively, it may merely manifest as a detectable signal without any direct mechanistic significance. Given that causality cannot be determined based on abundance alone, we propose a compartment-cell temporal framework: pathogenic effects may arise when lipid composition, flux or localisation exceed the tissue’s adaptive capacity. Experimental evidence plays a causal role for certain cholesterol and fatty acid pathways, whilst human lipid research remains at the stage of exploring associations. Lipid stress, through dysregulation of organelles such as the endoplasmic reticulum and mitochondria, converges with common features of joint ageing—including cellular senescence, mitochondrial dysfunction, imbalances in autophagy and proteostasis, inflammation, and alterations in signalling—and may reconcile previous conflicting findings in areas such as apolipoprotein E and fatty acid oxidation. At the translational level, weight loss and metabolic management are feasible short-term strategies, and the prospects for lipid stratification are promising; however, testing has not yet met clinical diagnostic standards, and lipid nanoparticles have not yet been established as a therapeutic method. At present, they should be regarded as delivery vehicles; challenges such as joint preservation, deep tissue delivery, and safety still need to be overcome, and validation in human tissue is required. In summary, lipid research contributes to the classification and treatment of OA, but a strict distinction must be made between the maturity of causal evidence and mere correlation.
- Open Access
- 29 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Plasma catecholamine metabolites are associated with disease activity and pathophysiological features in systemic lupus erythematosus using targeted LC–MS/MS
Systemic lupus erythematosus (SLE) presents diagnostic and disease monitoring challenges due to its heterogeneity and variable activity. In this cross-sectional study, we investigated the association of plasma catecholamine (CA) metabolites with SLE status and disease activity. Plasma samples from 88 SLE patients and 64 healthy controls were analyzed using targeted liquid chromatography-tandem mass spectrometry to quantify dopamine (DA), epinephrine (E), norepinephrine (NE), 3-methoxytyramine (3MT), metanephrine (MN), and normetanephrine (NMN). Significant alterations in CA metabolites levels were observed in SLE patients compared to controls, independent of glucocorticoid treatment. Orthogonal partial least squares-discriminant analysis (OPLS-DA) suggested distinct metabolic profiles in active SLE. NE, NMN, MN, and E showed notable group differences and correlations with inflammatory markers, clinical features, complement levels, and SLE Disease Activity Index (SLEDAI) scores. Receiver operating characteristic analysis demonstrated strong diagnostic performance for individual CA biomarkers, while combined plasma CA metabolites assessment yielded superior predictive capability for SLE activity (AUC: 0.866, 95% CI: 0.785–0.947). These findings highlight the potential of plasma CA metabolites, particularly NE and NMN, are associated with SLE disease activity and may serve as potential associative biomarkers. Further validation in independent and longitudinal cohorts is warranted.
- 29 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessPlasma catecholamine metabolites are associated with disease activity and pathophysiological features in systemic lupus erythematosus using targeted LC–MS/MS
Systemic lupus erythematosus (SLE) presents diagnostic and disease monitoring challenges due to its heterogeneity and variable activity. In this cross-sectional study, we investigated the association of plasma catecholamine (CA) metabolites with SLE status and disease activity. Plasma samples from 88 SLE patients and 64 healthy controls were analyzed using targeted liquid chromatography-tandem mass spectrometry to quantify dopamine (DA), epinephrine (E), norepinephrine (NE), 3-methoxytyramine (3MT), metanephrine (MN), and normetanephrine (NMN). Significant alterations in CA metabolites levels were observed in SLE patients compared to controls, independent of glucocorticoid treatment. Orthogonal partial least squares-discriminant analysis (OPLS-DA) suggested distinct metabolic profiles in active SLE. NE, NMN, MN, and E showed notable group differences and correlations with inflammatory markers, clinical features, complement levels, and SLE Disease Activity Index (SLEDAI) scores. Receiver operating characteristic analysis demonstrated strong diagnostic performance for individual CA biomarkers, while combined plasma CA metabolites assessment yielded superior predictive capability for SLE activity (AUC: 0.866, 95% CI: 0.785–0.947). These findings highlight the potential of plasma CA metabolites, particularly NE and NMN, are associated with SLE disease activity and may serve as potential associative biomarkers. Further validation in independent and longitudinal cohorts is warranted.
- 1 January 2025
- Vol. 55 (1) , 115-127
The Consistency of Plasma Catecholamines and Metanephrines Analysis in China: A Comparison of Three Mainstream Commercially Available Liquid Chromatography Tandem Mass Spectrometry Kit Methods.
The consistency of plasma catecholamines and metanephrines measurements is crucial for the screening and diagnosis in pheochromocytomas and paragangliomas (PPGLs). There are many commercially available kits for plasma catecholamines and metanephrines testing, but their performance and consistency information are unknown. This study evaluated the performance of three mainstream commercially available LC-MS/MS kit methods and evaluated their consistency. Performance validation of three kit methods was performed according to Clinical Laboratory Standards Institute (CLSI) document C-62A. 40 plasma samples from patients tested for PPGLs were analyzed in three mainstream commercially available kit methods. Agreement of test results from different kit methods was assessed by Passing-Bablok regression and Bland-Altman analysis. Recalibration using uniform calibrations was performed to identify the possible calibration difference. The performance of three mainstream commercially available LC-MS/MS kit methods was satisfied. The mean deviations ranges were as follows: epinephrine(E), -41.1% ~ -2.4%; norepinephrine (NE), -34.3% ~ -19.1%; metanephrine (MN), -6.5% ~ 0.3% and normetanephrine (NMN), -2.3% to 0.0%. After recalibration, the mean deviation ranges of the E and NE were reduced remarkably (E: -18% to -2.4%, NE: -19.1% to 8.0%). For MN and NMN, the consistency between the three commercially available kit methods is acceptable. The results for the E and NE showed unsatisfying comparability for almost all method pairs. The application of uniform calibrators could improve consistency among the mainstream systems for the measurement of plasma catecholamines.
- 1 January 2025
- Vol. 55 (1) , 115-127
The Consistency of Plasma Catecholamines and Metanephrines Analysis in China: A Comparison of Three Mainstream Commercially Available Liquid Chromatography Tandem Mass Spectrometry Kit Methods.
The consistency of plasma catecholamines and metanephrines measurements is crucial for the screening and diagnosis in pheochromocytomas and paragangliomas (PPGLs). There are many commercially available kits for plasma catecholamines and metanephrines testing, but their performance and consistency information are unknown. This study evaluated the performance of three mainstream commercially available LC-MS/MS kit methods and evaluated their consistency. Performance validation of three kit methods was performed according to Clinical Laboratory Standards Institute (CLSI) document C-62A. 40 plasma samples from patients tested for PPGLs were analyzed in three mainstream commercially available kit methods. Agreement of test results from different kit methods was assessed by Passing-Bablok regression and Bland-Altman analysis. Recalibration using uniform calibrations was performed to identify the possible calibration difference. The performance of three mainstream commercially available LC-MS/MS kit methods was satisfied. The mean deviations ranges were as follows: epinephrine(E), -41.1% ~ -2.4%; norepinephrine (NE), -34.3% ~ -19.1%; metanephrine (MN), -6.5% ~ 0.3% and normetanephrine (NMN), -2.3% to 0.0%. After recalibration, the mean deviation ranges of the E and NE were reduced remarkably (E: -18% to -2.4%, NE: -19.1% to 8.0%). For MN and NMN, the consistency between the three commercially available kit methods is acceptable. The results for the E and NE showed unsatisfying comparability for almost all method pairs. The application of uniform calibrators could improve consistency among the mainstream systems for the measurement of plasma catecholamines.
- Open Access
- 26 February 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (3)
Gut microbiota and metabolic biomarkers in metabolic dysfunction–associated steatotic liver disease
Metabolic dysfunction–associated steatotic liver disease (MASLD), a replacement of the nomenclature employed for NAFLD, is the most prevalent chronic liver disease worldwide. Despite its high global prevalence, NAFLD is often under-recognized due to the absence of reliable noninvasive biomarkers for diagnosis and staging. Growing evidence suggests that the gut microbiome plays a significant role in the occurrence and progression of NAFLD by causing immune dysregulation and metabolic alterations due to gut dysbiosis. The rapid advancement of sequencing tools and metabolomics has enabled the identification of alterations in microbiome signatures and gut microbiota-derived metabolite profiles in numerous clinical studies related to NAFLD. Overall, these studies have shown a decrease in α-diversity and changes in gut microbiota abundance, characterized by increased levels of Escherichia and Prevotella, and decreased levels of Akkermansia muciniphila and Faecalibacterium in patients with NAFLD. Furthermore, bile acids, short-chain fatty acids, trimethylamine N-oxide, and tryptophan metabolites are believed to be closely associated with the onset and progression of NAFLD. In this review, we provide novel insights into the vital role of gut microbiome in the pathogenesis of NAFLD. Specifically, we summarize the major classes of gut microbiota and metabolic biomarkers in NAFLD, thereby highlighting the links between specific bacterial species and certain gut microbiota-derived metabolites in patients with NAFLD.
- 26 February 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (3)
Open AccessGut microbiota and metabolic biomarkers in metabolic dysfunction–associated steatotic liver disease
Metabolic dysfunction–associated steatotic liver disease (MASLD), a replacement of the nomenclature employed for NAFLD, is the most prevalent chronic liver disease worldwide. Despite its high global prevalence, NAFLD is often under-recognized due to the absence of reliable noninvasive biomarkers for diagnosis and staging. Growing evidence suggests that the gut microbiome plays a significant role in the occurrence and progression of NAFLD by causing immune dysregulation and metabolic alterations due to gut dysbiosis. The rapid advancement of sequencing tools and metabolomics has enabled the identification of alterations in microbiome signatures and gut microbiota-derived metabolite profiles in numerous clinical studies related to NAFLD. Overall, these studies have shown a decrease in α-diversity and changes in gut microbiota abundance, characterized by increased levels of Escherichia and Prevotella, and decreased levels of Akkermansia muciniphila and Faecalibacterium in patients with NAFLD. Furthermore, bile acids, short-chain fatty acids, trimethylamine N-oxide, and tryptophan metabolites are believed to be closely associated with the onset and progression of NAFLD. In this review, we provide novel insights into the vital role of gut microbiome in the pathogenesis of NAFLD. Specifically, we summarize the major classes of gut microbiota and metabolic biomarkers in NAFLD, thereby highlighting the links between specific bacterial species and certain gut microbiota-derived metabolites in patients with NAFLD.